NCT06692166 is a Phase 3 clinical trial of 9MW2821 in Cervical Cancer, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd..

Who is sponsoring NCT06692166?

NCT06692166 is sponsored by Mabwell (Shanghai) Bioscience Co., Ltd..

What drugs are being tested in NCT06692166?

Interventions in NCT06692166: 9MW2821, Chemotherapy.

What condition does NCT06692166 study?

NCT06692166 studies Cervical Cancer.

Is NCT06692166 still recruiting?

NCT06692166 is currently recruiting now. Last updated 22 November 2024.

Last reviewed 2024-11-22 · How we verify

NCT06692166

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Recruiting now Phase 3 Last updated 22 November 2024

What this trial tests

Phase 3 trial testing 9MW2821 in Cervical Cancer in 420 participants. Currently enrolling.

Timeline

10 September 2024

Primary endpoint
9 December 2027

31 December 2029

Quick facts

Lead sponsor	Mabwell (Shanghai) Bioscience Co., Ltd.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	420
Start date	10 September 2024
Primary completion	9 December 2027
Estimated completion	31 December 2029
Sites	2 locations across China

Drugs / interventions tested

9MW2821 — full drug profile →
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the efficacy and safety of 9MW2821 and chemotherapy in participants with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study.
Zhang J, Liu R, Wang S, Feng Z, et al · · 2025 · cited 8× · PMID 40288679 · DOI 10.1016/j.annonc.2025.04.009
Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.
Katoh M, Loriot Y, Nakayama I, Hamada A, et al · · 2025 · PMID 41164107 · DOI 10.3389/fmmed.2025.1661016

Verify or expand the search:

Other trials of 9MW2821

Trials testing the same drug.

NCT07314723 — 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer · Phase 2 · recruiting
NCT06551233 — Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC) · Phase 1 · recruiting
NCT06079112 — 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT05773937 — A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors · Phase 1 · recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Mabwell (Shanghai) Bioscience Co., Ltd. trials

Trials by the same sponsor.

NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07314723 — 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer · Phase 2 · recruiting
NCT06926998 — 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors · Phase 1, PHASE2 · not yet recruiting
NCT06804590 — A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis · Phase 3 · recruiting
NCT06752746 — A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Poly · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06692166 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mabwell (Shanghai) Bioscience Co., Ltd.
Last refreshed: 22 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06692166.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing